Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash from Operations: 2023-2025

Historic Cash from Operations for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $100.4 million.

  • Monte Rosa Therapeutics' Cash from Operations rose 578.37% to $100.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.1 million, marking a year-over-year increase of 360.31%. This contributed to the annual value of $42.0 million for FY2024, which is 195.88% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Cash from Operations stood at $100.4 million, which was up 389.25% from -$34.7 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Cash from Operations high stood at $128.9 million for Q4 2024, and its period low was -$45.5 million during Q1 2025.
  • Its 3-year average for Cash from Operations is $1.7 million, with a median of -$24.7 million in 2023.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 63.06% in 2024, then spiked by 578.37% in 2025.
  • Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Cash from Operations stood at $29.6 million in 2023, then soared by 335.05% to $128.9 million in 2024, then skyrocketed by 578.37% to $100.4 million in 2025.
  • Its last three reported values are $100.4 million in Q3 2025, -$34.7 million for Q2 2025, and -$45.5 million during Q1 2025.